Solid Biosciences Inc. received FDA clearance for its Duchenne Muscular Dystrophy gene therapy candidate, SGT-003, and plans to begin a Phase 1/2 clinical trial.
AI Assistant
SOLID BIOSCIENCES INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.